NR4A1 and ductal breast carcinoma in situ: Patients with No‐DCIS were 1.6 times more likely to develop disease progression in contrast to IDC‐DCIS (OR: 1.6, 95% CI: 1.1–2.6, p = .027) but this risk was not significant after adjusting for T and N stage, overall stage, grade of tumor, presence of lymphovascular invasion, hormonal receptor status (OR:1.4 95% CI: 0.9–2.2, p = .205).